BioTime and Aastrom Biosciences -- Stem Cell Research Making Breakthroughs
06 March 2012 - 12:20AM
Marketwired
February was a challenging month for stem cell stocks. TickerSpy's
Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over
the last month -- underperforming the S&P 500 by close to 17
percent over that time frame. Despite the drop in investor
optimism, new and promising research continues to propel the
industry forward. Five Star Equities examines the outlook for
companies in the Biotechnology industry and provides equity
research on BioTime, Inc. (NYSE Amex: BTX) and Aastrom Biosciences,
Inc. (NASDAQ: ASTM). Access to the full company reports can be
found at:
www.fivestarequities.com/BTX
www.fivestarequities.com/ASTM
A new study at Johns Hopkins University has shown that stem
cells from patients' own cardiac tissue can be used to heal scarred
tissue after a heart attack. "This has never been accomplished
before, despite a decade of cell therapy trials for patients with
heart attacks. Now we have done it," Eduardo Marban, director of
the Cedars-Sinai Heart Institute and one of the study's co-authors,
said in a statement. "The effects are substantial."
In another study, researchers led by Jonathan Tilly, director of
the Vincent Center for Reproductive Biology at Massachusetts
General Hospital, argue they've discovered the ovaries of young
women harbor very rare stem cells capable of producing new
eggs.
Five Star Equities releases regular market updates on the
biotechnology industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.fivestarequities.com
and get exclusive access to our numerous stock reports and industry
newsletters.
Aastrom Biosciences, Inc., a regenerative medicine company,
engages in developing autologous cell therapies for the treatment
of severe and chronic cardiovascular diseases.
BioTime, Inc. primarily focuses on regenerative medicine, which
refers to therapies based on human embryonic stem (hES) cell and
induced pluripotent stem (iPS) cell technology designed to rebuild
cell and tissue function lost due to degenerative disease or
injury. The company recently elected to market progenitors of
muscle stem cells bearing hereditary diseases. BioTime will produce
the products from five human embryonic stem (hES) cell lines from
Reproductive Genetics Institute (RGI) of Chicago, Illinois.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.fivestarequities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024